CTX001
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Beta-Thalassemia
Conditions
Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
Trial Timeline
Jan 20, 2021 → Sep 30, 2039
NCT ID
NCT04208529About CTX001
CTX001 is a phase 3 stage product being developed by Vertex Pharmaceuticals for Beta-Thalassemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04208529. Target conditions include Beta-Thalassemia, Thalassemia, Sickle Cell Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05477563 | Phase 3 | Recruiting |
| NCT05356195 | Phase 3 | Active |
| NCT05329649 | Phase 3 | Active |
| NCT04208529 | Phase 3 | Recruiting |
| NCT03745287 | Phase 2/3 | Completed |
| NCT03655678 | Phase 2/3 | Completed |
Competing Products
18 competing products in Beta-Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-536 | Merck | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Zoledronic acid + Placebo | Novartis | Phase 2/3 | 65 |
| deferasirox | Novartis | Phase 3 | 77 |
| ICL670 + deferoxamine | Novartis | Phase 3 | 77 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| ICL670 | Novartis | Approved | 85 |
| Bitopertin | Roche | Phase 2 | 52 |
| Luspatercept + Placebo | Bristol Myers Squibb | Phase 2 | 51 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 76 |
| CTX001 | Vertex Pharmaceuticals | Phase 2/3 | 64 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 76 |
| Mozobil + Mozobil + Mozobil | Sanofi | Pre-clinical | 22 |
| Deferitrin (GT56-252) + desferoxamine (DFO) | Sanofi | Phase 1/2 | 40 |
| REGN7999 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + Placebo | LabCorp | Phase 2 | 49 |
| VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + Placebo | LabCorp | Phase 2 | 49 |